X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs AUROBINDO PHARMA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA AUROBINDO PHARMA SANOFI INDIA/
AUROBINDO PHARMA
 
P/E (TTM) x 30.0 17.7 168.9% View Chart
P/BV x 5.3 5.8 91.8% View Chart
Dividend Yield % 1.7 0.4 474.0%  

Financials

 SANOFI INDIA   AUROBINDO PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
AUROBINDO PHARMA
Mar-16
SANOFI INDIA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs4,5601,541 296.0%   
Low Rs4,400582 756.0%   
Sales per share (Unadj.) Rs1,028.5237.5 433.1%  
Earnings per share (Unadj.) Rs129.033.9 380.8%  
Cash flow per share (Unadj.) Rs186.040.6 458.3%  
Dividends per share (Unadj.) Rs68.002.50 2,720.0%  
Dividend yield (eoy) %1.50.2 644.4%  
Book value per share (Unadj.) Rs753.6120.6 624.9%  
Shares outstanding (eoy) m23.03585.17 3.9%   
Bonus/Rights/Conversions -PREF-  
Price / Sales ratio x4.44.5 97.5%   
Avg P/E ratio x34.731.3 110.9%  
P/CF ratio (eoy) x24.126.2 92.1%  
Price / Book Value ratio x5.98.8 67.5%  
Dividend payout %52.77.4 714.4%   
Avg Mkt Cap Rs m103,174621,041 16.6%   
No. of employees `0003.613.3 27.3%   
Total wages/salary Rs m3,59215,508 23.2%   
Avg. sales/employee Rs Th6,537.710,457.6 62.5%   
Avg. wages/employee Rs Th991.41,167.1 84.9%   
Avg. net profit/employee Rs Th819.81,491.6 55.0%   
INCOME DATA
Net Sales Rs m23,686138,961 17.0%  
Other income Rs m7081,663 42.6%   
Total revenues Rs m24,394140,624 17.3%   
Gross profit Rs m5,28132,056 16.5%  
Depreciation Rs m1,3133,926 33.4%   
Interest Rs m152,568 0.6%   
Profit before tax Rs m4,66127,225 17.1%   
Minority Interest Rs m039 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6917,444 22.7%   
Profit after tax Rs m2,97019,820 15.0%  
Gross profit margin %22.323.1 96.7%  
Effective tax rate %36.327.3 132.7%   
Net profit margin %12.514.3 87.9%  
BALANCE SHEET DATA
Current assets Rs m15,673100,015 15.7%   
Current liabilities Rs m6,67874,759 8.9%   
Net working cap to sales %38.018.2 208.9%  
Current ratio x2.31.3 175.4%  
Inventory Days Days76107 70.8%  
Debtors Days Days22110 20.4%  
Net fixed assets Rs m8,09852,350 15.5%   
Share capital Rs m230585 39.4%   
"Free" reserves Rs m17,08867,707 25.2%   
Net worth Rs m17,35670,567 24.6%   
Long term debt Rs m08,472 0.0%   
Total assets Rs m25,400156,994 16.2%  
Interest coverage x311.711.6 2,686.6%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.90.9 105.4%   
Return on assets %11.814.3 82.4%  
Return on equity %17.128.1 60.9%  
Return on capital %26.937.7 71.4%  
Exports to sales %24.551.0 48.0%   
Imports to sales %28.018.8 148.4%   
Exports (fob) Rs m5,80170,927 8.2%   
Imports (cif) Rs m6,62726,193 25.3%   
Fx inflow Rs m7,14571,015 10.1%   
Fx outflow Rs m6,84628,799 23.8%   
Net fx Rs m29942,216 0.7%   
CASH FLOW
From Operations Rs m3,22617,596 18.3%  
From Investments Rs m-1,555-13,801 11.3%  
From Financial Activity Rs m-1,818-198 916.8%  
Net Cashflow Rs m-1473,597 -4.1%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 8.0 181.1%  
FIIs % 14.6 27.7 52.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 10.2 102.9%  
Shareholders   15,184 69,601 21.8%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   VENUS REMEDIES  MERCK LTD  GSK PHARMA  J.B.CHEMICALS  ORCHID PHARMA LTD  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Recovery of Global Markets, Apex Frozen Food IPO & Cues to Watch Out Today(Pre-Open)

Indian stock markets remained range-bound in lacklustre trade on Tuesday as market participants kept to the sidelines in the absence of clear triggers.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Aug 22, 2017 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS